________________________________________________________________________________________________________________________
This extensive network supports an extensive product portfolio that is organized into three segments:
■ STADA’ s Consumer Healthcare segment includes a range of non-prescription products, such as OTC medicines, medical devices, cosmeceuticals and cosmetics and vitamin supplements, plus consumer products such as the household disinfectant Zoflora. Beyond Zoflora, other top-selling products in the Consumer Healthcare include the Nizoral scalp-care range, Grippostad and SNUP( cough and cold), Paracetamol STADA and Ibuprofen STADA for pain-relief, and the chamomile-based Kamistad brand.
■ STADA’ s Generics segment focuses on prescription drugs that require a prescription and are available exclusively through pharmacies and / or hospitals. Generics offer a lower cost alternative to the substantially more expensive pharmaceutical originator products. Patent expirations and loss of regulatory market exclusivity of originator drugs feed this Generics product pipeline in the Generics segment, which encompasses a wide range of therapeutic areas including antibiotics, cardiology, gastroenterology and pain relief.
■ As STADA’ s fastest-growing business segment, Specialty encompasses biosimilars- biologic medicinal products that are almost identical to existing originator biologic products by demonstrating that they do not differ in a clinically meaningful way – as well as medicines designed for designed for chronic, complex, rare or genetic uses. This category includes innovative medicinal products addressing unmet clinical needs, such as for Parkinson’ s disease or the first medicine approved in the EU and the UK for treating a rare, debilitating kidney disease.
... successfully expanded from a small pharmaceutical undertaking focused on its domestic German market into a leading player in the international healthcare and pharmaceutical markets
The Germany-based group’ s R & D activities are primarily focused on product development that translates new scientific discoveries into useful products. Through an established, international network of development hubs with a highly skilled workforce, the group employs specialty and complex technologies. A strong network of co-development partnerships enables the group to minimize upfront investments into in-house capacities. This strategy has resulted in a strong launch track record, as reflected by well over 1,000
104